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Background: HCC predominantly develops in the condition of chronic inflammation that has led to liver cirrhosis.
A small proportion of patients with HCC is diagnosed in the non-cirrhotic liver (NCL). Data on patients with HCC in
NCL in advanced stages are scarce.
Methods: A retrospective analysis was performed comparing 93 patients with HCC in NCL to 571 patients with
HCC in liver cirrhosis (LC) with respect to clinical and demographic characteristics. Also factors influencing survival
in patients with HCC in NCL were analyzed.
Results: Patients with HCC in NCL were diagnosed at older age and in more advanced tumor stages than patients
with LC. More than 25% of patients with HCC in NCL presented with extrahepatic metastases. Only a minority of
patients with HCC in NCL lacked any sign of hepatic damage. Risk factors for LC and risk factors for NAFLD are
present in the majority of patients with HCC in NCL. The BCLC classification corresponded with the survival of
patients with HCC in NCL although the therapeutic options differ from those for patients with liver cirrhosis.
Conclusions: It will be one of the major challenges in the future to awake awareness of carrying a risk of hepatic
malignancies in patients with chronic liver diseases apart from liver cirrhosis, especially in NAFLD. Surveillance
programs need to be implemented if these are cost-effective.
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The incidence of hepatocellular carcinoma (HCC) is con-
stantly rising throughout the world with the majority of
cases in Asia and Africa due to the high prevalence of
hepatitis B virus (HBV) infection [1]. Although Europe is
still considered to be a low incidence area, the incidence
of HCC in Germany has risen [2] to 6.2 cases/100 000/
year with a high mortality of 5.2/100 000/year [3]. HCC
develops predominantly in the condition of chronic in-
flammation evolving into liver cirrhosis (LC) [2]. There-
fore liver function in addition to tumor stage and patient* Correspondence: peter.malfertheiner@med.ovgu.de
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unless otherwise stated.related factors has a major impact on treatment decision
and prognosis in case of HCC.
The proportion of patients with HCC diagnosed in a
non-cirrhotic liver (NCL) varies throughout different
geographic regions of the world ranging from 7% to 54%
and depends strongly on the leading risk factor for hepa-
tocarcinogenesis [4]. In Western countries, 15%-20% of
HCCs are diagnosed in the absence of LC [1,5,6]. Most
reports on these patients are from surgically treated co-
horts of patients that have undergone curative resection
with an obvious selection bias. Data on patients with
HCC in NCL in more advanced stages with respect to
clinical features and factors influencing survival are
scarce in Europe.
Strikingly, previous studies reveal a lower male prepon-
derance of HCC in NCL than in LC. The three main risk
factors for HCC (HBV or HCV infection and alcoholl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with HCC in NCL present at more advanced tumor stages
than patients with HCC in LC [4,7] because tumors are
generally detected when the disease has become symp-
tomatic. The reason for this is that HCC in LC are fre-
quently detected during surveillance ultrasound. However,
a larger proportion of patients with HCC in NCL can be
treated with curative intent because hepatic resections
without the risk of postoperative liver failure are more
likely. The absence of advanced underlying chronic liver
disease leads to the fact that the tumor burden is the most
significant factor influencing survival among further
tumor-related, demographic and etiological factors [4,5].
Methods
Aiming at a clinical characterization of patients with
HCC in NCL, a retrospective analysis in a large single-
center cohort in Germany was performed. Patients with
HCC in NCL were compared to patients with HCC in
LC with respect to demographic and clinical characteris-
tics. Additionally, factors influencing the survival of pa-
tients with HCC in NCL were analyzed.
The medical records of 714 patients diagnosed and
treated with HCC at the University Hospital of Magde-
burg between February 1994 and January 2013 were ana-
lyzed retrospectively. The analysis included patients who
were referred to the Department of Gastroenterology,
Hepatology and Infectious Diseases, to the Department
of Surgery or to the Department of Radiology and Nuclear
Medicine. After excluding patients in whom sufficient
data was not available for the purpose of this study, 664
patients were included into the final analysis. Of these,
571 were diagnosed with HCC in LC and 93 patients
(14.01%) suffered from HCC in a non-cirrhotic liver.
The retrospective analysis was performed following
the guidelines of the Declaration of Helsinki and ap-
proved by the ethical review committee of the Otto-von-
Guericke University Magdeburg, Germany.
Epidemiological data
Age, gender, height, weight, calculation of body mass
index (BMI) and performance status at the time of diag-
nosis were recorded.
Liver cirrhosis was either diagnosed histologically or
by typical clinical signs, i.e. findings consistent with por-
tal hypertension (enlarged spleen, ascites, esophageal or
gastric varices or portal hypertensive gastropathy) com-
bined with sonographical findings. The diagnosis of a
non-cirrhotic liver was based on reports of the histo-
pathological evaluation of liver tissue obtained by sur-
gery at time of the resection of HCC or obtained by
biopsy from the non-tumor-tissue at the time of diagno-
sis of HCC. Patients without histological sampling were
classified as non-cirrhotic if they were completely free ofany evidence of cirrhosis based on clinical, laboratory
and radiological findings.
Liver cirrhosis was considered to be a consequence of
chronic alcohol abuse if the patient had reported a con-
sumption of more than 60 g alcohol/day or if a history
of chronic alcohol abuse was documented in the past
medical history. Data on the status of hepatitis B viral
infection was available for all and on hepatitis C virus in-
fection for 643 patients.
Information on prevalence of diabetes mellitus as a
metabolic risk factor was available for 427 patients.
NAFLD was diagnosed by criteria for steatosis in trans-
abdominal ultrasound in the absence of other possible
causes of liver disease.
Serum parameters
To diligently characterize underlying chronic liver dis-
ease with respect to liver function, inflammatory activ-
ity and etiology, a panel of parameters on clinical chemistry
were extracted from the medical records. These in-
cluded levels of bilirubin, albumin, quick, prothrombin
time, alkaline phosphatase, gamma-glutamyl transferase,
alanine aminotransferase, aspartate aminotransferase,
creatinine, hemoglobin, platelet count, urea nitrogen
and protein. If available, levels of ferritin, transferrin sat-
uration, immunoglobulin (Ig) G, IgA, IgM, coeruloplas-
min, antinuclear antibodies, antibodies against soluble
liver antigen, anti-liver kidney microsomal antigen and
alpha-1-antitrypsin were analyzed, too. Additionally, the
level of alpha-fetoprotein (AFP) at the time of diagnosis
was evaluated. All serum parameter values were classi-
fied according to a specified threshold for explorative
analyses on parameters’ impact on survival.
Tumor stage
Radiological reports were used for the assessment of
tumor stage. Number and size of HCC nodules as well
as the presence of distant metastases including lymph
node involvement and information on the patency of the
portal vein were recorded. The Barcelona-Clinic Liver
Cancer (BCLC) stage was defined respecting tumor stage,
liver function as assessed by Child-Pugh-score in patients
with LC and clinical performance status of the patient [8].
Additionally, the CLIP score was rated for all patients if
possible [9,10].
Survival data
In 397 cases the exact date of death was taken from the
medical records. For the remaining patients, data on sur-
vival was censored at the time of the last documented
contact to the patient. Thus, the length of survival was
calculated from the date of HCC diagnosis to the date of
death or to the date of the last documented contact,
respectively.
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All statistical analyses were performed using IBM SPSS
Statistics 21.0.0 (IBM Corporation, New York, N.Y.,
USA). Results for numerical data are given as median
together with minimum and maximum of the sample
(i.e. range). For categorical data, results are given as ab-
solute numbers with percentage. For comparison of
categorical data, Chi-Square-tests were applied. Mann–
Whitney U–tests were used for testing homogeneity of
independent samples in continuous data. For the ana-
lysis of individual factors influencing survival Cox re-
gression analyses were performed. Factors that were
shown to have a significant input on patients’ survival at
univariate analysis were included into a multivariate Cox
regression analysis except for the two staging systems
(CLIP score and BCLC score) that are influenced by sev-
eral of the clinical and tumor related factors. Median
survival times that were also compared by log-rank tests
and Kaplan-Meier curves are given for single influencing
factors. All tests were carried out two-sided. The level of
significance was set to 0.05 without adjusting for multi-
plicity. The analysis has to be regarded as explorative.
Results
The demographic characteristics of patients analyzed are
summarized in Table 1. Patients with LC and HCC were
diagnosed at a median age of 66 years (range 31–85
years) while patients with HCC in NCL were diagnosed
at a statistically significant older age (median age 69 years
(range 32–85 years), p = 0.004) (Figure 1).Table 1 Patients’ demographic characteristics










3 or 4 0
Diabetes mellitus Yes 42 (n = 59)






p-values indicating a statistical significance are printed in bold.Of 571 patients with HCC in LC, 103 were female,
resulting in a male to female ratio of 4.5:1 while the pro-
portion of female patients was larger in patients with HCC
in NCL with a male to female ratio of 2.7:1 (p = 0.045). Fe-
male patients were diagnosed with HCC in NCL at a me-
dian age of 66 years while male patients presented at a
median age of 71 years (p = 0.383). No statistically signifi-
cant differences between patients with HCC in NCL and
patients with HCC in LC were depicted with respect to
their clinical performance status at the time of diagnosis.
When analyzing potential underlying liver diseases or
risk factors for the development of HCC, significant dif-
ferences between the two cohorts were apparent. While
in a significant proportion of patients with LC alcohol
was identified as causative factor, alcoholic liver disease
played a minor role in patients with HCC in NCL and
was identified in 15.05% of patients. Viral hepatitis was
diagnosed in 7.53% of patients with HCC in NCL (HCV
n = 3; HBV n = 4). NAFLD was diagnosed in 6 patients
(6.5%). Of these 6 patients, 5 suffered from diabetes mel-
litus, 5 had been diagnosed with arterial hypertension
and 4 presented with a BMI > 25 kg/m2. With respect to
all patients with HCC in NCL, the BMI exceeded 25 kg/
m2 in 31 (33.3%) patients, 8 patients (8.6%) were obese
and presented with a BMI exceeding 30 kg/m2. A signifi-
cant proportion of patients with HCC in NCL had been
diagnosed with diabetes mellitus (n = 42, 45.16%), in 27
patients (29%) a clinical diagnosis of steatosis of the liver
had been established before. In the majority of patients
(n = 53; 56.99%) with HCC in NCL no underlying= 93 HCC in LC; n = 571 p
%/range n/median %/range
73 468 82 0.045
27 103 18
32-85 66 31-85 0.004
19.18-38.5 27.1 18.07-46.30 <0.001





71.2 308 (n = 368) 83.7 0.020
40.0 110 (n = 231) 47.6 0.308





Figure 1 Age distribution of patients with HCC in NCL and LC at initial diagnosis.
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of patients the prevalence of metabolic risk factors was
also high: 37.74% suffered from diabetes mellitus, 58.5%
from arterial hypertension and 22.64% presented with a
BMI ≥ 25 kg/m2.
A histopathological report regarding the tumor tissue
was available in 87 (93.5%) patients. In 21 patients with
HCC in NCL the histopathological evaluation of non-
neoplastic liver tissue revealed fibrosis of different de-
grees, in 18 patients fatty liver disease was diagnosed, in
8 patients no fibrosis was detected in non-neoplastic
liver tissue.
A comparison of tumor stage at diagnosis revealed
that patients with HCC in NCL were diagnosed in more
advanced tumor stages than patients with HCC in LC.
More than half of the patients with HCC in NCL were
in BCLC stage C (51.6% compared to 42.4% of patients
with HCC in LC), every third patient was diagnosed in
intermediate stage (BCLC B, 34.4% in comparison to
29.6% of patients with HCC in LC). Tumor related char-
acteristics of the two cohorts are summarized in Table 2.
Although diagnosed more frequently as uninodular dis-
ease (49.46%) than in patients with LC, HCC in NCL
were larger than those in LC and were diagnosed more
frequently with extrahepatic metastases. The prevalence
of portal vein thrombosis was equal between the two co-
horts. Ascites was more frequent in patients with HCC
in LC.
The proportion of patients with serum AFP concentra-
tion exceeding 200 ng/ml was almost similar between
the two groups (33.3% in NCL vs 37.0% in LC).In the laboratory work-up of the two cohorts (Table 3)
statistically significant differences were apparent with re-
spect to liver function at time of diagnosis of HCC.
Patients with HCC in LC showed statistically significant
elevated concentrations of bilirubin, ASAT, GGT and IgA
as well as prolonged PTT in comparison to patients with
HCC in NCL. Concentrations of parameters mirroring
liver synthesis capacity (quick, albumin) and platelets were
significantly lower in patients with HCC in LC compared
to non-cirrhotic patients. All other parameters evaluated
did not show statistically significant differences.
In a univariate Cox regression analysis for factors influ-
encing survival of patients with HCC in NCL the presence
of portal vein thrombosis, the presence of extrahepatic
metastases, concentration of AFP, ASAT and platelets as
well as the ECOG performance status of the patient were
significant factors. A multivariate analysis of these factors
confirmed the presence of extrahepatic metastases and
the concentration of platelets as factors significantly influ-
encing survival of patients with HCC in NCL (Table 4).
The unadjusted results of further univariate explorative
analyses are given in Figures 2 (demographic parameters
and tumor related parameters) and 3 (staging systems).
Regarding the two staging systems applied, the BCLC
system correlated better with the survival of patients
with HCC in NCL than the CLIP score (Figure 3).
Overall survival according to tumor stage at diagnosis
did not differ significantly between patients with HCC in
NCL and patients with HCC in liver cirrhosis. Patients di-
agnosed in BCLC A showed a median survival of 945 days
(SD 17) in case of NCL compared to 951 days (SD 176,
Table 2 Tumor related characteristics of the two cohorts
Parameter HCC in NCL; n = 93 HCC in LC; n = 571 p
n/median %/range n/median %/range
Number of nodules n = 93 n = 569 0.053
1 46 49.46 213 37.43
2 5 5.38 60 10.54
≥3 42 45.16 296 52.02
Size of largest nodule (cm) 9.1 2-20 6.5 1-22 0.002
Distribution of nodules Left liver lobe 24 25.81 184 32.22 0.123
Right liver lobe 34 36.56 157 27.50
Both liver lobes 28 30.11 207 36.25
No data 7 7.52 23 4.03
Portal vein thrombosis n = 86 n = 517 0.732
Yes 27 31.4 172 33.27
No 59 69.6 345 66.73
Extrahepatic metastasis n = 86 n = 508 0.028
Yes 32 37.21 131 25.79
No 54 62.79 377 74.21
Ascites n = 84 n = 535 < 0.001
Yes 17 20.24 237 44.30
no 67 79.76 298 55.70
BCLC stage n = 93 n = 571 0.006
A 13 14 100 17.5
B 32 34.4 169 29.6
C 48 51.6 242 42.4
D 0 0 60 10.5
CLIP score n = 82 n = 483 0.015
0 14 17.07 60 12.42
1 20 24.39 111 22.98
2 16 19.51 103 21.33
3 25 30.49 88 18.22
4 5 6.1 59 12.22
5 2 2.44 52 10.77
6 0 0 10 2.07
p-values indicating a statistical significance are printed in bold.
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dian survival of 925 days (SD 189) in comparison to
501 days (SD 58, p = 0.100) in case of LC. For patients
with advanced disease the median survival was 229 days
(SD 34) compared to 209 days (SD 15, p = 0.438).
First-line treatment modalities applied in patients with
HCC in NCL are summarized in Table 5. In summary,
30.12% of patients underwent treatment in curative intent
(resection, liver transplantation or local ablation).
Discussion
Most of the characteristics reported in the literature over
the last decades were confirmed in our analysis, but wealso identified some differences compared to published
data [4,11].
In 14% of our study population HCC has been detected in
NCL. Patients with HCC in NCL presented at an older age
than patients with HCC in LC and this differs from some of
the previous reports [12,13]. We confirmed a larger propor-
tion of female patients with HCC in NCL. In both cohorts
of patients, with and without LC, more than 50% of patients
initially presented with symptoms and impaired perform-
ance status. A previous study from Germany states that 47%
of patients present with tumor symptoms leading to the ini-
tial diagnosis of HCC, but 86% of patients with HCC in
NCL are not restricted in their daily activities at all [5].
Table 3 Laboratory work-up of patients with HCC in NCL in comparison to patients with HCC in LC
Parameter (SI-units) Patients with HCC in NCL Patients with HCC in LC p
n Median Range n Median Range
Bilirubin 88 11.5 3.3-497.0 547 20.6 3.3-709.1 < 0.001
Quick 89 97.0 18-120 547 86.0 18-120 < 0.001
Albumin 81 40.10 15.6-71.0 507 36.1 9.5-72.5 < 0.001
ALAT 87 0.75 0.04-7.72 545 0.77 0.12-31.20 0.110
ASAT 86 0.76 0.17-12.11 546 1.11 0.26-25.90 < 0.001
GGT 80 2.43 0.19-36.28 518 3.26 0.17-66.51 0.002
Alcaline phosphatase 81 3.59 0.38-36.46 506 3.41 0.69-138.69 0.737
Creatinine 87 78.00 45-480 535 77.0 2-557 0.622
Urea nitrogen 83 5.8 2.1-44.2 513 5.9 1.6-35.8 0.437
Ferritin 32 452.5 21-2928 233 356.0 3-7585 0.553
Transferrin saturation 29 25.50 8.0-95.3 166 30.3 4.5-119.0 0.310
Coeruloplasmin 16 0.38 0.29-0.53 112 0.36 0.12-2.31 0.951
Hemoglobin 82 8.2 5.7-18.7 505 8.1 4.1-13.7 0.997
Platelets 81 261.0 84-693 506 166.5 33-799 < 0.001
PTT 84 28.5 22.1-60.0 527 31.5 19.2-80.2 < 0.001
IgA 15 2.56 0.61-22.80 101 5.42 1.27-43.30 < 0.001
IgM 13 0.970 0.5-2.6 96 1.19 0.2-15.5 0.274
IgG 14 13.05 8-28 103 16.30 2-46 0.117
CA 19-9 22 35.5 1.5-7520 226 60.00 <0.5-8483.0 0.057
AFP 85 32.10 1-378813.00 531 62.00 0.6-1460000.00 0.168
ALAT = alanine aminotransferase, ASAT = aspartate aminotransferase, GGT = gamma glutamyl transferase, PPT = partial thromboplastin time, IgA = immunoglobulin
A, IgG = immunoglobulin G, AFP = alpha fetoprotein, CA 19–9 = carbohydrate antigen 19–9.
p-values indicating a statistical significance are printed in bold.
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ology was most likely related to the metabolic syndrome.
Even though non-alcoholic fatty liver disease (NAFLD)
was diagnosed in a small proportion of patients, factors
of the metabolic syndrome were frequent in our cohort,
especially in the subgroup of patients in whom no other
risk factor was identified. NAFLD, the hepatic manifest-
ation of the metabolic syndrome, is frequently under-
diagnosed in the general population but is recognized to
be a frequent cause for HCC [14]. The incidence of cir-
rhosis, on the other hand, in patients with HCC and
NAFLD is low in comparison to patients with other
causes of HCC [15], and patients with HCC and NAFLD
exhibit more features of the metabolic syndrome [15].
Vice versa, about 75% of obese patients suffer from
NAFLD [16], and obesity alone has been shown to be a
risk factor for HCC with an OR of 1.39 to 4.52 [17-19].
Several cohort studies have demonstrated that diabetes
mellitus is an independent risk factor for hepatocellular
carcinoma [20]. An analysis within the SEER-database
found a 2.9 fold risk for diabetic patients to develop
HCC [21]. This risk factor was present in more than
70% of our patients with HCC in NCL.It is suggested that tumor suppressor genes play an
important role in the development of steatosis, induce
liver cell damage and therefore promote the formation
of HCC in the absence of cirrhosis [15,22,23] in combin-
ation with other complex dysregulated mechanisms and
pathways in fatty liver disease.
It is striking that, although a direct hepatocarcinogenic
role of alcohol has not been proven so far, 15% of pa-
tients with HCC in NCL reported a significant intake of
alcohol as risk factor for liver disease. This goes along
with data previously reported in which 12% to 21.4% of
patients with HCC in NCL abused alcohol [4,5,7]. This
suggests that cirrhosis is not a condition sine qua non in
alcoholic liver disease for HCC development. It is not
known whether in these patients the inflammation alone
is sufficient or whether fibrosis needs to develop before
HCC can arise. A Swedish study demonstrated a 2.4 fold
risk for hepatocellular carcinoma in patients with alco-
hol abuse in comparison to the general population that
increased to a 22.4 fold risk in the presence of cirrhosis
[24]. An interaction between alcoholic liver disease and
other risk factors is likely to occur. Hence, obesity and
the metabolic syndrome are factors which favor the
Table 4 Cox regression analysis for factors influencing survival in patients with HCC in NCL
Variables (SI-units if not indicated
otherwise)
Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
Age (≤65 years vs > 65 years) 1.598 0.957-2.669 0.073
Sex (m vs f) 0.777 0.457-1.332 0.352
BMI (≤30 kg/m2 vs > 30 kg/m2) 0.573 0.216-1.518 0.263
Etiology (alcohol vs viral vs other) 0.095
BCLC stage 0.014
CLIP 0.031
Size of largest nodule (>5 cm vs≤ 5 cm) 1.991 0.993-3.992 0.052
Portal vein thrombosis (yes vs no) 1.859 1.066-3.241 0.029 1.559 0.676-3.596 0.298
Extrahepatic metastasis (yes vs no) 2.104 1.248-3.549 0.005 2.844 1.098-7.368 0.031
Ascites 1.181 0.575-2.428 0.651
Number of lesions (one vs two vs multinodular) 0.204
Steatosis (yes vs no) 0.576 0.248-1.340 0.200
AFP 1.0 0.999-1.000 0.031 1.0 0.999-1.001 0.323
CA 19-9 1.0 0.999-1.001 0.969
Hemoglobin 0.963 0.790-1.174 0.709
ALAT 1.060 0.864-1.302 0.575
ASAT 1.158 1.000-1.340 0.050 0.999 0.629-1.586 0.997
Albumin 0.975 0.941-1.010 0.152
Bilirubin 1.001 0.997-1.006 0.484
Alcaline phosphatase 0.993 0.955-1.032 0.724
GGT 1.021 0.974-1.071 0.386
Quick 0.990 0.977-1.002 0.112
PTT 1.057 1.007-1.110 0.026 1.057 0.891-1.255 0.524
Platelets 1.002 1.000-1.004 0.049 1.004 1.001-1.007 0.006
Ferritin 1.0 1.000-1.001 0.455
Creatinine 0.997 0.992-1.002 0.231
Urea nitrogen 0.966 0.914-1.020 0.212
Diabetes mellitus (yes vs no) 1.246 0.564-2.753 0.586
Nicotine (yes vs no) 1.239 0.632-2.428 0.532
ECOG status (1 or 2 vs 0) 1.965 1.129- 3.417 0.017 1.645 0.681-3.968 0.269
Aim of treatment (palliative vs curative) 1.044 0.616-1.770 0.873
p-values indicating a statistical significance are printed in bold.
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tocellular carcinoma (HCC) incidence and mortality
[25]. Similarly, a synergism has been shown for viral hepa-
titis and heavy alcohol consumption [26]. Viral hepatitis
played a minor role in our cohort.
Since we did not take biopsies from non-tumorous
liver tissue as part of the standard work-up of patients
with HCC, the number of patients with histology from
non-tumorous tissue is rather small. Patients without
any hepatic damage of the tissue surrounding the tumor
were few and this may indicate the possibility of direct
hepatocarcinogenesis in the healthy liver (e.g. adenoma-
carcinoma sequence). Most patients showed histologicalfeatures of chronic liver damage. Chronic liver disease
thus may not have been recognized in advance of hepa-
tocellular carcinoma and therefore no surveillance has
been offered. This is probably the reason why diagnosis
is made in advanced tumor stages in these patients.
Consistent with previous studies almost every second
patient with HCC in NCL was diagnosed with a single tu-
morous nodule but of larger size [11,27]. The proportion
of patients with extrahepatic metastases in our cohort
exceeded 25% and was strikingly larger than reported in
other cohorts [5,28] with up to 15%.
The BCLC staging system, although developed for pa-
tients with LC, correlates with patients’ survival. The
Figure 2 Univariate explorative analysis of factors influencing survival in patients with HCC in NCL. A age: ≤ 65 years vs > 65 years.
B ECOG performance status: 1 or 2 vs 0. C presence of extrahepatic metastases yes vs no. D presence of portal vein thrombosis yes vs no.
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tients with HCC in NCL. Patients in intermediate stage
HCC according to BCLC in NCL show a trend towards
prolonged survival in comparison to patients with LC.
This is most likely because curative treatment can be of-
fered to these patients even if the tumor load exceeds
the Milan criteria.
Survival of patients with HCC in NCL mainly depends
on tumor related factors such as tumor size, existence of
satellite lesions, existence of a tumor capsule, vascular in-
vasion, grading, R0 resection and the amount of intraoper-
ative blood transfusions [28-35]. Analyses from mixed
surgically and medically treated cohorts of patients identi-
fied tobacco consumption, clinical performance status,
siderosis of non-tumorous tissue, tumor stage according
to BCLC and the initial treatment to be relevant forsurvival [5,7]. Our study confirms tumor related factors to
exert a significant influence on patients’ outcome in uni-
variate explorative analyses (portal vein thrombosis, exist-
ence of extrahepatic tumor manifestations). Tumor size
and number of intrahepatic HCC nodules had not statisti-
cally significant impact on survival. Ongoing hepatic in-
flammation, mirrored in elevation of ASAT, reduced
hepatic synthesis capacity mirrored in prolonged PTT and
low platelets (probably a consequence of portal hyperten-
sion caused by portal vein thrombosis or by large hepatic
tumor load) were negative predictive for survival for pa-
tients with HCC in NCL. At multivariate analysis solely
the presence of metastases and low platelets were signifi-
cant factors influencing survival.
Although the proportion of patients who presented at
an early tumor stage was rather small, it was evident that
Figure 3 Univariate explorative analyses of survival of patients with HCC in NCL in dependence of tumor stage according to BCLC and
CLIP-score. A survival (days) according to BCLC score A vs B vs C. B survival (days) according to CLIP score 0 vs 1 vs 2 vs 3 vs 4–6.
Schütte et al. BMC Gastroenterology 2014, 14:117 Page 9 of 10
http://www.biomedcentral.com/1471-230X/14/117in addition to patients in BCLC A some patients at an
intermediate tumor stage (BCLC B) also qualified for
treatment in curative intent. A modification of current
treatment algorithms for patients with HCC in NCL is
desirable.
Our study has some limitations due to the retrospect-
ive design and the small number of patients in some of
the univariate analyses might lead to insignificant find-
ings in the statistical analyses. The mixed cohort of pa-
tients does not permit to address surgical aspects.Table 5 Treatment modalities applied in patients with





Treatment modality n % n %
Curative treatment Resection 22 23.66 69 12.1
RFA/thermoablation 5 5.38 27 4.7
Liver transplantation 1 1.08 8 1.4
Total 28 30.11 104 18.2
Palliative treatment Transarterial
chemoembolization




22 23.66 167 29.3
Y90-radioembolisation 3 3.23 23 4.0
HD-interstitial
brachytherapy
12 12.90 52 9.1
Best supportive care 5 5.38 20 3.5
Total 56 60.22 390 68.3
No data 9 9.68 77 13.5Conclusion
HCC in NCL has distinct features compared to HCC in
LC. The majority of patients with HCC in NCL present
with signs of hepatic damage even in the absence of
LC. Risk factors for LC and risk factors for NAFLD are
present in the majority of these patients and surveil-
lance programs need to be implemented if these are
cost-effective.
In this cohort the proportion of patients with advanced
tumor stage and especially with extrahepatic metastases
was larger than expected from previously published
surgically treated cohorts. The BCLC staging algorithm
correlates with patients’ survival. However, therapeutic
decisions should not be based on this staging system as
in non-cirrhotic patients curative treatment can be of-
fered also to patients with large intrahepatic tumors
outside the Milan criteria.
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